Drug Pricing
Biosimilars
The Biosimilar Promise
Low-Cost Biosimilars Are Saving Billions, Potential Savings Are Even Greater
Low-Cost Biosimilars Are Saving Billions, Potential Savings Are Even Greater By Wayne Winegarden | October 28, 2024 READ PDF Executive Summary Since 2019, biosimilars have obtained a majority share of most markets where they compete. The combination of lower prices (both biosimilar and originator) and rising market share could ...
Commentary
Learn more about how government intervention is harming the healthcare market
Trump vs. Harris on Health Care: Experts Explain Each Side
“He and his colleagues believe that patients are not in control of the health care system and that we suffer from an opaque and complex pricing structure that harms patients. “Winegarden’s free market approach means he advocates for doing away with the Obamacare subsidies that Congress must consider, as they ...
Commentary
Learn more about how price fixing stifles innovation
New Schizophrenia Drug Represents Promise Of Pharmaceutical Innovation
Late last month, the U.S. Food and Drug Administration approved Bristol Myers Squibb’s KarXT, a treatment for schizophrenia. The drug, which will be marketed under the brand name Cobenfy, is promising not just because it is effective at treating the debilitating mental health condition. It also seems not to have the potentially harmful side ...
Commentary
Learn more about how price controls are driving physician shortages
Price Controls Are Harming Doctors
Whether its pharmaceuticals or health insurance, Vice President Kamala Harris appears to have only one healthcare policy – impose price controls. The untenable financial position of many doctors and private doctor practices due to tightening Medicare reimbursement rates exemplifies the folly of her preferred approach. As I document in a recent ...
340B. drug pricing
How The Hospital Industrial Complex Robs Poor Patients
Pharmaceutical leader Johnson & Johnson recently unleashed a firestorm in Washington after it proposed a change to how it offers discounted prices on two drugs in a little-known, but enormous, federal program that’s hurting the low-income patients it was created to help. That program, known as the “340B Drug Pricing Program,” allows ...
Commentary
Harris’s Farcical Price Control Schemes
Karl Marx famously said that history repeats itself first as tragedy, then as farce. Vice President Kamala Harris is bringing that aphorism to life by putting price controls at the center of her economic agenda. Despite centuries of evidence that such controls invariably lead to shortages, rationing and general economic ...
Biosimilars
The Biosimilar Promise
Biosimilars Often Reduce Prices by 50 Percent or More
Biosimilars Often Reduce Prices by 50 Percent or More By Wayne Winegarden | October 1, 2024 READ PDF Executive Summary In the competitive biologic markets, biosimilars have reduced average prices by 56 percent. The lower prices have reduced total expenditures by 51 percent in the competitive biologic markets even though ...
Commentary
Learn how PBMs pocket savings intended for patients
How Long Can Pharmacy Benefit Managers Go Unchecked?
Last week, a House subcommittee held a hearing on pharmacy benefit managers and their impact on the prices patients pay for prescription drugs. The hearing speaks to voters’ concerns. Republicans and Democrats alike have identified the cost of prescription drugs as their No. 2 health care concern, according to polling ...
Blog
Learn how drug price controls hurt patients, innovation
Senator Sanders’ Price Controls Will Harm Patients
In a patently politicized press release, Senator Bernie Sanders (I-VT) who is Chairman of the Senate Health, Education, Labor, and Pensions (HELP) Committee, claims that the U.S. price of Ozempic is too high. As evidence, he cites generic companies that claim they can sell Ozempic for less than $100 a ...
Commentary
Drug Companies Are Embracing Direct-To-Consumer Sales. That’s A Win For Patients.
Fortunately, that’s starting to change. In recent months, drug companies Pfizer and Eli Lilly have begun rolling out direct-to-consumer programs that let patients purchase basic prescriptions remotely. This development is a huge win for patients. Not only are direct-to-consumer offerings more convenient. They can also provide a jolt of competition ...
The Biosimilar Promise
Low-Cost Biosimilars Are Saving Billions, Potential Savings Are Even Greater
Low-Cost Biosimilars Are Saving Billions, Potential Savings Are Even Greater By Wayne Winegarden | October 28, 2024 READ PDF Executive Summary Since 2019, biosimilars have obtained a majority share of most markets where they compete. The combination of lower prices (both biosimilar and originator) and rising market share could ...
Learn more about how government intervention is harming the healthcare market
Trump vs. Harris on Health Care: Experts Explain Each Side
“He and his colleagues believe that patients are not in control of the health care system and that we suffer from an opaque and complex pricing structure that harms patients. “Winegarden’s free market approach means he advocates for doing away with the Obamacare subsidies that Congress must consider, as they ...
Learn more about how price fixing stifles innovation
New Schizophrenia Drug Represents Promise Of Pharmaceutical Innovation
Late last month, the U.S. Food and Drug Administration approved Bristol Myers Squibb’s KarXT, a treatment for schizophrenia. The drug, which will be marketed under the brand name Cobenfy, is promising not just because it is effective at treating the debilitating mental health condition. It also seems not to have the potentially harmful side ...
Learn more about how price controls are driving physician shortages
Price Controls Are Harming Doctors
Whether its pharmaceuticals or health insurance, Vice President Kamala Harris appears to have only one healthcare policy – impose price controls. The untenable financial position of many doctors and private doctor practices due to tightening Medicare reimbursement rates exemplifies the folly of her preferred approach. As I document in a recent ...
How The Hospital Industrial Complex Robs Poor Patients
Pharmaceutical leader Johnson & Johnson recently unleashed a firestorm in Washington after it proposed a change to how it offers discounted prices on two drugs in a little-known, but enormous, federal program that’s hurting the low-income patients it was created to help. That program, known as the “340B Drug Pricing Program,” allows ...
Harris’s Farcical Price Control Schemes
Karl Marx famously said that history repeats itself first as tragedy, then as farce. Vice President Kamala Harris is bringing that aphorism to life by putting price controls at the center of her economic agenda. Despite centuries of evidence that such controls invariably lead to shortages, rationing and general economic ...
The Biosimilar Promise
Biosimilars Often Reduce Prices by 50 Percent or More
Biosimilars Often Reduce Prices by 50 Percent or More By Wayne Winegarden | October 1, 2024 READ PDF Executive Summary In the competitive biologic markets, biosimilars have reduced average prices by 56 percent. The lower prices have reduced total expenditures by 51 percent in the competitive biologic markets even though ...
Learn how PBMs pocket savings intended for patients
How Long Can Pharmacy Benefit Managers Go Unchecked?
Last week, a House subcommittee held a hearing on pharmacy benefit managers and their impact on the prices patients pay for prescription drugs. The hearing speaks to voters’ concerns. Republicans and Democrats alike have identified the cost of prescription drugs as their No. 2 health care concern, according to polling ...
Learn how drug price controls hurt patients, innovation
Senator Sanders’ Price Controls Will Harm Patients
In a patently politicized press release, Senator Bernie Sanders (I-VT) who is Chairman of the Senate Health, Education, Labor, and Pensions (HELP) Committee, claims that the U.S. price of Ozempic is too high. As evidence, he cites generic companies that claim they can sell Ozempic for less than $100 a ...
Drug Companies Are Embracing Direct-To-Consumer Sales. That’s A Win For Patients.
Fortunately, that’s starting to change. In recent months, drug companies Pfizer and Eli Lilly have begun rolling out direct-to-consumer programs that let patients purchase basic prescriptions remotely. This development is a huge win for patients. Not only are direct-to-consumer offerings more convenient. They can also provide a jolt of competition ...
